Medodermone

Clobetasol propionate.

Medodermone Cream and Ointment each contain 0.05% w/w Clobetasol propionate.

Clobetasol propionate is a very active topical corticosteroid which is of particular value when used in short courses for the treatment of more resistant dermatoses such as psoriasis, recalcitrant eczemas, lichen planus, discoid lupus erythematosus, and other conditions which do not respond satisfactorily to less-active steroids.

Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly-active topical steroid preparations, therapy should be discontinued when control is achieved. In the more responsive conditions this may be within a few days. If a longer course is necessary, it is recommended that treatment should not be continued for more than four weeks without the patient's condition being reviewed. Repeated short courses of Clobetasol may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used.
In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Clobetasol can be enhanced, if necessary, by occluding the treatment area with polythene film. Overnight occlusion only is usually adequate to bring about a satisfactory response. Thereafter improvement can usually be maintained by application without occlusion.

Rosacea, acne and peri-oral dermatitis.
Skin lesions caused by infection with viruses (e.g. herpes simplex, chickenpox), fungi (e.g. candidiasis, tinea) or bacteria (e.g. impetigo).
Hypersensitivity to the preparation.

Visual disturbance: Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
Long-term continuous therapy with Clobetasol should be avoided, particularly in infants and children, in whom adrenal suppression occurs readily. If Clobetasol is required for use in children, it is recommended that the treatment should be reviewed weekly. It should be noted that the infant's napkin may act as an occlusive dressing.
The face, more than other areas of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. This must be borne in mind when treating facial conditions which warrant use of Clobetasol and frequent observations of the patient is important. If applied to the eyelids, care is needed to ensure that the preparation does not enter the eye, as glaucoma might result.
Appropriate antimicrobial therapy should be used whenever treating inflammatory lesions which have become infected. Any spread of infection requires withdrawal of topical corticosteroid therapy and institution of suitable systemic chemotherapy.
Bacterial infection is encouraged by the warm, moist conditions induced by occlusive dressings, and the skin should be cleansed before a fresh dressing is applied.
Topical administration of corticosteroids to pregnant animals can cause abnormalities of fetal development. The relevance of this finding to human beings has not been established; however, topical steroids should not be used extensively in pregnancy, i.e. in large amounts or for prolonged periods.

Eye: Vision, blurred.
Provided the weekly dosage is less than 50g in adults, any pituitary adrenal suppression is likely to be transient with a rapid return to normal values once the short course of steroid therapy has ceased. The same applies to children given proportionate dosage. Use of occlusive dressings increases the absorption of topical corticosteroids.
Prolonged and intensive treatment with highly-active corticosteroid preparations may cause atrophic changes, such as striae, thinning of the skin, and dilatation of the superficial blood vessels, particularly when occlusive dressings are used, or where skin folds are involved.
In rare instances, treatment of psoriasis with corticosteroids (or its withdrawal) is thought to have provoked the pustular form of the disease.
Clobetasol is usually well tolerated, but if signs of hypersensitivity appear, application should be stopped immediately.

Incompatibility:Clobetasol is incompatible with alkalis.

Store in a cool place.

Topical Corticosteroids

D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.

POM